Trial · NCT03605680
Adverse events28
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 28
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dry Mouth | Gastrointestinal disorders | Placebo: SB Run-in Period Only | 0 | 138 | |
| other | Dry Mouth | Gastrointestinal disorders | Placebo + Centanafadine SR 200 mg | 6 | 149 | |
| other | Dry Mouth | Gastrointestinal disorders | Placebo + Centanafadine SR 400 mg | 9 | 149 | |
| other | Dry Mouth | Gastrointestinal disorders | Placebo + Placebo | 0 | 148 | |
| other | Upper respiratory tract infection | Infections and infestations | Placebo: SB Run-in Period Only | 0 | 138 | |
| other | Upper respiratory tract infection | Infections and infestations | Placebo + Centanafadine SR 200 mg | 8 | 149 | |
| other | Upper respiratory tract infection | Infections and infestations | Placebo + Centanafadine SR 400 mg | 1 | 149 | |
| other | Upper respiratory tract infection | Infections and infestations | Placebo + Placebo | 3 | 148 | |
| other | Decreased appetite | Metabolism and nutrition disorders | Placebo: SB Run-in Period Only | 0 | 138 | |
| other | Decreased appetite | Metabolism and nutrition disorders | Placebo + Centanafadine SR 200 mg | 9 | 149 | |
| other | Decreased appetite | Metabolism and nutrition disorders | Placebo + Centanafadine SR 400 mg | 11 | 149 | |
| other | Decreased appetite | Metabolism and nutrition disorders | Placebo + Placebo | 2 | 148 | |
| other | Headache | Nervous system disorders | Placebo: SB Run-in Period Only | 2 | 138 | |
| other | Headache | Nervous system disorders | Placebo + Centanafadine SR 200 mg | 5 | 149 | |
| other | Headache | Nervous system disorders | Placebo + Centanafadine SR 400 mg | 7 | 149 | |
| other | Headache | Nervous system disorders | Placebo + Placebo | 14 | 148 | |
| serious | Gastroenteritis viral | Infections and infestations | Placebo: SB Run-in Period Only | 0 | 138 | |
| serious | Gastroenteritis viral | Infections and infestations | Placebo + Centanafadine SR 200 mg | 1 | 149 | |
| serious | Gastroenteritis viral | Infections and infestations | Placebo + Centanafadine SR 400 mg | 0 | 149 | |
| serious | Gastroenteritis viral | Infections and infestations | Placebo + Placebo | 0 | 148 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03605680/events